|
- Home - Oncoinvent
Transform cancer care through direct alpha therapy Interview with CEO by Infront Direkt Studios 10th November, 2025 Latest news and press releases 18 Dec 2025 Oncoinvent ASA: Notice of Extraordinary General Meeting
- About Oncoinvent
Oncoinvent ASA is a Norwegian clinical-stage biotech company with a vision to transform cancer care through direct alpha therapy Oncoinvent ASA was founded in 2010 by Dr Roy H Larsen, Professor of Clinical Oncology Øyvind Bruland, Dr Tina Bønsdorff, and Dr Thora Jonasdottir
- News - Oncoinvent
Press Release 01 2018: Oncoinvent is pleased to announce today that Oncoinvent researchers have published data demonstrating the efficacy of the Radspherin® in two separate models of peritoneal carcinomatosis originating from ovarian cancer cell lines in the journal Translational Oncology
- Pipeline - Oncoinvent
At Oncoinvent we aspire to transform cancer care through direct alpha therapy We are actively seeking strategic partnerships to advance our drug development and maximize the potential of our pipeline
- News Events - Oncoinvent
Oncoinvent ASA Announces Positive Safety Review of Lead-In Cohort, Advances to Randomised Part of Ongoing Phase 2 Trial of Radspherin® in Ovarian Cancer Patients
- Radspherin® - Oncoinvent
Radspherin®, Oncoinvent’s lead product candidate, is a novel alpha radiation therapy candidate designed for the local treatment of cancers that have spread to body cavities
- Management - Oncoinvent
News Events Newsletter subscription Reports and presentations The Share IR Contact +47 22 18 33 05 Oncoinvent ASA Gullhaugveien 7 0484 Oslo Norway
- Oncoinvent Announces Agreement with ARTBIO to Collaborate on . . .
Oncoinvent ASA is a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers The technology platform is focused on the use of alpha-emitting radionuclides to deliver powerful radiation directly to cancer cells
|
|
|